1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedarplus.ca under the Company’s profile.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Publishes on Apabetalone’s Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
October 4, 2023
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
August 29, 2023
Resverlogix Announces Warrant Repricing and One-Year Extension
June 29, 2023
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
June 20, 2023
Resverlogix Announces New Insights into the Mechanism of Apabetalone’s Cardioprotective Benefit in Chronic Kidney Disease Patients
June 12, 2023
Resverlogix Announces One-Year Extension of Debenture
March 20, 2023
Resverlogix Announces New Research Highlighting Apabetalone’s Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
March 2, 2023